PEAR: Experimental Outcomes

• Research type

  Research Study

• Full title

  PEAR study: experimental outcomes

• IRAS ID

  182893

• Contact name

  Magdi Yaqoob

• Contact email

  m.m.yaqoob@qmul.ac.uk

• Sponsor organisation

  Barts Health NHS Trust

• Duration of Study in the UK

  0 years, 11 months, 30 days

• Research summary

  Primary Endpoint

  To study the effect of pentoxifylline on cytokine levels in ESRD patients on haemodialysis with hypo-responsiveness to erythropoiesis stimulating agents or ESAs.

  Secondary Endpoint

  To study effect of pentoxifylline on leucocyte DNA telomere length shortening and highly sensitive CRP levels

  Methodology
  Laboratory analysis of blood samples stored for future research as a part of PEAR study

  Research Sites
  Barts Health NHS Trust- Royal London Hospital
  Objectives/Aims
  To study the effect of Pentoxifylline on cytokine levels, leucocyte DNA telomere length shortening and Highly sensitive c reactive protein compared to control group.

  Number of Participants/Patients 69

  Main Inclusion Criteria
  Samples already collected from PEAR study
  Statistical Methodology and Analysis (if applicable)
  Analysis will include descriptive statistics, t­test, Paired­t variance and covariance and use of non­parametric statistics when required.

  Proposed Start Date 1 June 1015

  Proposed End Date 15. Dec.2016

• REC name

  North West - Preston Research Ethics Committee

• REC reference

  15/NW/0513

• Date of REC Opinion

  12 Jun 2015

• REC opinion

  Favourable Opinion